文 | 智能相对论 作者 | 华安 这世界什么东西是绝对公平的？ 只有死亡 有钱没钱 没有人能逃脱 越是有钱人 到了那个时候 就越舍不得 全球富豪都在想尽各种办法给自己续命 这其中就包括今年已经97岁的李嘉诚 两个月前 台湾摇滚乐队"五月天"在香港举办演唱会 歌迷李嘉诚也来到现场 这场搏斗十几年前就开始了 李嘉诚80来岁的时候 就开始频繁、大额支持健康、长寿科技的发展 2011年 李嘉诚基金会向加州大学伯克利分校捐款4000万美元 兴建"李嘉诚生物医学和健康科学中心" 只不过是坐着电动三轮车来的 曾经叱咤风云的华人首富 现在已经老态龙钟 不得不令人唏嘘 但是 李嘉诚毕竟是富豪 他不像普通人那样"坐以待毙" 对长寿科技的投入 早已经开始 年初的时候 李嘉诚突然以45亿低价 将家族持有24年的上海和黄药业股权 给卖了 很多人认为这是正常的商业选择 不看好了就离场 但资金去向却很有意思 李嘉诚旗下维港投资 将这笔钱注资到了以色列Pluristem公司 这个公司研发间充质干细胞技术 这种技术是干嘛的呢？ 我们人体所有器官都是从原始的干细胞分化来的 不同干细胞有不同用途 比如造血干细胞可以治疗白血病 而以色列这个公司研 ...

本报讯(记者金婉霞)7月4日，在上海举行的"好望角科学沙龙"精准医疗专场活动上，信达生物制药集团 创始人、董事会主席、首席执行官俞德超表示："细胞与基因治疗、双特异性抗体、抗体药物偶联物 (ADC)等新疗法的市场增长潜力巨大，而人工智能的快速发展，又给治愈疾病提供了更多可能性。" 中科创星创始合伙人米磊表示，新兴生物技术正以底层科技突破为引擎，逐渐改变人类的生命健康观 念，从曾经的"对抗疾病"转向"掌控生命质量"，从过去的"群体经验"迈向"个体精准"。在老龄化、慢病 化成为人类生命健康主要矛盾的当下，还要依托政策的支持、资本的耐心和公众的理解，共同推动精准 医疗成为人类健康事业的新支柱。 长期从事细胞命运调控基础理论研究的欧洲科学院院士裴端卿则在沙龙上分享了关于干细胞治疗的观 点。他表示，实验室的一系列技术表明，尿液的上皮细胞里面可以重新找回受精后四到五天的多能性状 态的细胞，"这些细胞的应用前景非常广阔，我们可以把它变成多能干细胞，也可以变成神经干细胞， 神经干细胞特别在神经退行性疾病的治疗中有非常好的应用前景。"裴端卿说。此外，他还分享了如何 将干细胞转变成干细胞制剂、干细胞功能分化后的提取物、类器官等干 ...

工信部消费品司司长何亚琼、北京市经信局局长姜广智、中国医药企业管理协会副会长王学恭、昌平区 区长刘晓东共同参与了"北京未来医药产业链研究院(筹)揭牌仪式"。该研究院将开展医药产业链发展研 究，支撑关键技术协同攻关，组织政产学研医金合作，推动医药产业国际化发展，服务医药产业区域协 同发展，打造我国医药领域高水平智库和产业服务平台。 本报讯(记者张敏)7月6日，第42届全国医药工业信息年会和2025北京.昌平生命科学论坛在北京昌平开 幕。本次活动由北京市经济和信息化局，北京市科学技术委员会、中关村科技园区管理委员会，北京市 药品监督管理局，北京市科学技术协会，北京市昌平区人民政府联合主办；中国医药工业信息中心和北 京未来科学城管理委员会承办。 国家药品监督管理局副局长黄果在会议上提到，2025年上半年，国家药监局批准上市创新药达到43款， 其中由中国企业研发制造的有40款，跨国企业研发进口3款。今年1月份，北京企业研发的全国首个干细 胞药物获批上市，多家跨国企业纷纷宣布在北京建设创新研发中心，这些标志性的成果充分彰显了北京 医药创新的实力、活力，未来可期。 国家医保局医药服务管理司司长黄心宇对近日发布的《支持创新 ...

Core Viewpoint - The planned 500 million yuan private placement by Guanhao Biotech has been officially terminated after more than two years of planning due to changes in the market environment and considerations of the company's overall development strategy [2][6]. Group 1: Private Placement Details - The private placement was initially approved by the shareholders in April 2023, but the company delayed the implementation multiple times, extending the validity of the resolution [3]. - In January 2024, Guanhao Biotech submitted the application to the Shenzhen Stock Exchange, which was accepted, but the company again extended the resolution's validity in March 2024 [4]. - The termination of the private placement comes after the company had planned to issue up to 55,803,571 shares at a price of 8.96 yuan per share, while the current stock price is 16.41 yuan per share, representing an increase of over 80% [5]. Group 2: Financial Implications - The company has a funding gap of 623 million yuan, which includes minimum cash reserves, repayment of short-term loans, and future large expenditures [6]. - As of the first quarter of 2024, Guanhao Biotech reported cash holdings of 122 million yuan against current liabilities of 146 million yuan [7]. Group 3: Business Performance - Guanhao Biotech's revenue dropped significantly by 22.84% in 2022 to 377 million yuan, with a net loss of 308 million yuan, but there was a recovery in 2023 [8]. - However, in 2024, both revenue and net profit are projected to decline again, with revenue decreasing by 6.60% to 377 million yuan and net profit down by 11.57% to 27.42 million yuan [8]. - The decline in revenue is attributed to decreased income from core products, particularly in the medical device and pharmaceutical sectors [8]. Group 4: Strategic Focus - Guanhao Biotech is shifting its focus towards the cell therapy sector, having established a research and application platform for cell and stem cell technology since 2013 [9]. - The company is currently developing projects in the cell field, including a bioartificial liver and mesenchymal stem cell therapy, both of which are in preclinical research [9]. - The termination of the private placement raises concerns about the viability of the company's "cell strategy," especially as R&D expenditures have been declining for three consecutive years [9].

二是不良反应增多。非正常渠道来源的注射材料，如假冒的肉毒素、所谓的生长因子、干细胞，成 份不明，注射往往容易引起严重的过敏反应，局部的肉芽肿，异常增生，甚至中毒。 三是栓塞风险增大。注射美容对医生的技术有很高要求，需要非常精细把握面部或者其他部位的解 剖特点，非专业人员进行注射治疗容易误将这些填充物注入到血管，引发血管的栓塞，导致皮肤坏死、 失明或者是脑梗。 中国医学科学院整形外科医院主任医师王永前表示，医疗美容是用手术、药物、医疗器械或者是其 他具有创伤性、侵入性的医学技术方法，对人的容貌和各部位的形态进行修复或者重塑。例如，双眼皮 手术、激光美容、打除皱针等。整形外科主要做组织修复与重建，侧重于疾病的治疗，例如唇裂修复、 瘢痕整形。生活美容是非侵入性的美容服务，比如贴敷面膜，不在医疗场所开展。 "提供医疗美容服务的机构必须是医疗机构。"王永前说，为了保证医疗美容服务的安全和质量，国 家对于医疗美容机构的设置和执业人员的资质有非常严格的要求，可以在国家卫健委官网查询医疗机构 的执业许可信息。 王永前提示，在生活美容机构或者在家自行做医疗美容是非常危险的，特别是注射美容，可能会导 致危及生命安全。主要风险如下 ...

Core Viewpoint - The article highlights the challenges faced by biopharmaceutical companies in Shenzhen regarding the approval of production licenses for standalone factory buildings, emphasizing the need for clearer regulations to support the industry's growth [1][2][3]. Group 1: Industry Challenges - Biopharmaceutical companies are struggling to find suitable standalone factory buildings of approximately 7,000 square meters for the commercialization of new stem cell drugs [1]. - The "industrial building up" policy in Shenzhen has not significantly benefited pharmaceutical companies, as they require standalone buildings to obtain production licenses [1]. - Many companies face a dilemma between choosing standalone buildings, which are more likely to receive production licenses but are often too large for their needs, and opting for "industrial building up," which carries the risk of not obtaining the necessary licenses [1]. Group 2: Regulatory Environment - The Guangdong Provincial Drug Administration has introduced a "one enterprise, one policy" approach to improve service for companies, but many firms find the limited successful cases of "industrial building up" to be of little reference value [2]. - The lack of clear and transparent rules creates uncertainty for biopharmaceutical companies, which are particularly vulnerable during their early stages of development [2]. - There is a call for the establishment of explicit rules for biopharmaceutical companies to alleviate the anxiety surrounding the approval process and to foster a more predictable regulatory environment [3].

Core Insights - The research team from Kunming University of Science and Technology successfully developed healthy live monkeys and genetically matched autologous embryonic stem cells from a single primate embryo using embryo splitting technology, marking a significant advancement in regenerative medicine [1][2] - The study published in the journal Nature Communications highlights the importance of obtaining genetically matched embryonic stem cells to address issues of immune rejection and ethical concerns associated with traditional stem cell therapies [1] Summary by Categories Research Methodology - The team optimized embryo splitting techniques by simulating the natural formation of identical twins, performing splits at the 4-cell and 8-cell stages, with a more efficient 3:5 strategy at the 8-cell stage [1] - From 23 pairs of split embryos, two healthy monkeys and autologous stem cell lines were successfully generated, with one case resulting in a successful cell line establishment before mid-pregnancy miscarriage [1] Findings and Comparisons - Single-cell transcriptome analysis revealed that autologous embryonic stem cells exhibited lower cell heterogeneity, reduced transcriptional noise, and more significant expression of genes related to genomic stability compared to induced pluripotent stem cells and somatic cell nuclear transfer embryonic stem cells [2] - Under feeder layer culture conditions, induced pluripotent stem cells showed a stronger differentiation trend, while autologous embryonic stem cells were more similar to somatic cell nuclear transfer embryonic stem cells [2] Clinical Implications - The establishment of autologous embryonic stem cells from split embryos presents a new method for generating pluripotent stem cells and provides an ideal model for assessing the functional differences of various stem cell types in vivo [2] - The research has potential clinical applications in organ repair and disease treatment, laying a crucial foundation for future regenerative medicine applications [2]

重组胶原蛋 白的"秘密"。 手工劳动/兽妹 手工编辑 /掘叔 出品/独角兽观察 2025年上半年，沉寂多时的商业江湖重新热闹起来，"商战"这一久违的戏码也在多个赛道上演。 互联网领域，京东与美团在外卖市场短兵相接，补贴大战硝烟再起。美妆行业，华熙生物与巨子生物两 巨头的"成分之战"也是打得如火如荼。 这场围绕重组胶原蛋白的技术标准之争，横跨一个多月，表面上是对市场份额的争夺，是对女性"脸 面"的争夺，实则是技术路线、行业标准与商业伦理的深层博弈。虽然关注度不如外卖那么高，但在中 国美妆史上必将留下浓墨重彩的一笔。 最后，以巨子生物承认现有检测方法有局限性，有待改进暂时画上句号，但这场堪称史诗级的商战对行 业带来的冲击和思考还没结束。 从研发缺位到炒概念狂欢，从标准真空到检测"罗生门"……这场"脸面之争"背后，是谁在透支行业的未 来？又将对行业未来竞争带来哪些变化？ 巨头的"脸面"之战 早在2023年初，业内就有消息称，快手正着手正式入局信贷领域，到了2023年末，快手进一步落实金融 野心，陆续招兵买马，其中涉及风控合规、供应链金融等方向的岗位。 很多媒体在复盘这场"脸面"之战时，会把5月24日，美妆博主"大嘴 ...

Core Viewpoint - The Daxing Biomedical Industry Base, known as "China Pharmaceutical Valley," is accelerating its development in the life and health industry, aiming for high-quality growth and international influence by 2025 [1][3][13]. Group 1: Industry Development - The life and health industry is a strategic emerging industry crucial for national security and public welfare, with Daxing District being a key area for its development in Beijing [3][4]. - The Daxing Biomedical Industry Base has expanded by 9.1 square kilometers, enhancing its capacity for industrial research and production, as well as supporting services [4]. - The base is set to strengthen its core industries, including vaccines, traditional Chinese medicine, and high-end medical devices, while also exploring new sectors like medical aesthetics and animal pharmaceuticals [7][13]. Group 2: Project Initiatives - Several high-impact biomedical projects are set to be established in the Daxing Biomedical Industry Base, including innovative drug development and antibody production [6]. - The second phase of the China Food and Drug Inspection Institute's project has commenced, significantly boosting the region's research and testing capabilities [5]. - The base is actively promoting the construction of a new campus for Capital Medical University, which will enhance research innovation and industry integration [4]. Group 3: Technological Integration - The Daxing Biomedical Industry Base is leveraging big data and artificial intelligence to enhance its service and digital capabilities across various sectors [8][10]. - The base is transitioning from a product-oriented approach to a service-oriented model, exemplified by the establishment of a new retail consumption model by Tongrentang Health [8]. - Advanced AI technologies are being integrated into drug research and development, marking a significant shift towards innovative pharmaceutical solutions [10]. Group 4: Policy and Support - The Daxing Biomedical Industry Base is implementing a "one-stop service platform" to optimize the business environment and support enterprises in accessing various policy benefits [12]. - The base has facilitated the application of over 50 projects for national and municipal policy support, enhancing the operational capabilities of more than 30 enterprises [12]. - The base is committed to fostering a collaborative ecosystem by establishing shared platforms for high-value instruments and equipment among research institutions [11].

活动现场，校方特意邀请9位分布在北京、上海等地的成功捐献校友返校，授予"荣誉校友"称号。 大连医科大学发出倡议，并成立由大连高校联合组建的新一届志愿宣讲团。 会后，百余名大学生纷纷卷起衣袖，陆续完成造血干细胞血样采集，他们将为更多的人带去生的希 望。 "2015年，我还是大三学生，就正式加入中华骨髓库，随时等待配型成功的呼唤，后来我毕业去北 京工业大学，还特意去红十字会更改变动的手机号，就怕失去联系……"活动现场，该校第23例捐献者 陈桐讲述起他的故事，在报名九年后，他终于和一位3岁的白血病患儿配型成功，并顺利完成捐献。 据介绍，21年来，大连医科大学持续开展"心相连 爱相随"造血干细胞捐献公益项目，将志愿服务 精神与医学生人文精神培养紧密结合，立足本校辐射全市高校，广泛开展科普宣讲活动，形成了做造血 干细胞志愿者光荣的良好氛围，4358名大医师生加入中华骨髓库，志愿采集率远高于全国平均水平。 新华网沈阳6月24日电（记者于力）这是一场跨越21年的生命接力，自2004年开始，大连医科大学 已累计招募4358名入库志愿者，开展18次捐献造血干细胞血样采集活动，配型成功并完成捐献23例，这 个数字占大连市捐献总量 ...